CDMOs investigate how to support GLP-1 manufacturing, pharma considers supply chain diversity: #Jefferies23
If there were two key ideas that sprung from the CDMO panel at this week’s Jefferies London Healthcare Conference, it is that manufacturers are reviewing how they can expand into GLP-1s and that securing supply chains is at the back of mind for clients.
There is booming demand for GLP-1s to the point that Sylke Hassel, CEO of API manufacturer Axplora, said that it’s akin to the surge of demand for Covid vaccines during the height of the pandemic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.